Tau imaging with [18F]THK-5351 in progressive supranuclear palsy

European Journal of Neurology

Volumn 24, Issue 1, 2017, Pages 130-136

  Ishiki, A ^a   Harada, R ^a   Okamura, N ^b,c   Tomita, N ^a   Rowe, C C ^d   Villemagne, V L ^d,e   Yanai, K ^b   Kudo, Y ^a   Arai, H ^a   Furumoto, S ^a   Tashiro, M ^a   Furukawa, K ^a,c  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^d AUSTIN HEALTH   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

positron emission tomography; progressive supranuclear palsy; tau

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B; RADIOPHARMACEUTICAL AGENT; TAU PROTEIN; THK 5351 F 18; UNCLASSIFIED DRUG; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; THIAZOLE DERIVATIVE;

AGED; AKINESIA; ALZHEIMER DISEASE; ARTICLE; AUTORADIOGRAPHY; BRAIN TISSUE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; FLUORESCENCE; FLUORESCENCE MICROSCOPY; FUSIFORM GYRUS; GAZE PARALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFERIOR TEMPORAL CORTEX; MALE; MINI MENTAL STATE EXAMINATION; MUSCLE RIGIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARAHIPPOCAMPAL GYRUS; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; TEMPORAL CORTEX; VERY ELDERLY; BRAIN; DIAGNOSTIC IMAGING; METABOLISM; PATHOLOGY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANILINE COMPOUNDS; BRAIN; FEMALE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS; THIAZOLES;

EID: 84996615294     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.13164     Document Type: Article

References (22)

1. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol 2015; 14: 114–124.
2. Villemagne VL, Okamura N. In vivo tau imaging: obstacles and progress. Alzheimers Dement 2014; 10(Suppl. 3): 254–264.
3. James OG, Doraiswamy PM, Borges-Neto S. PET imaging of tau pathology in Alzheimer's disease and tauopathies. Front Neurol 2015; 6: 38.
4. Williams DR. Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau. Intern Med J 2006; 36: 652–660.
5. Williams DR, Holton JL, Strand C, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain 2007; 130: 1566–1576.
6. Villemagne VL, Chételat G. Neuroimaging biomarkers in Alzheimer's disease and other dementias. Ageing Res Rev 2016; 30: 4–16.
7. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306–319.
8. George N, Gean EG, Nandi A, Frolov B,Zaidi E. Advances in CNS imaging agents: Focus on PET and SPECT tracers in experimental and clinical use. CNS Drugs 2015; 29: 313–330.
9. Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013; 79: 1094–1108.
10. Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013; 34: 457–468.
11. 18F-THK5105 PET. Brain 2014; 137: 1762–1771.
12. 18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2015; 42: 1052–1061.
13. Johnson KA, Schultz A, Betensky RA, et al. Tau PET imaging in aging and early Alzheimer's disease. Ann Neurol 2016; 79: 110–119.
14. 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer's disease. J Nucl Med 2016; 57: 208–214.
15. de Silva R, Lashley T, Gibb G, Hanger D. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol 2003; 29: 288–302.
16. Kumar A, Nisha CM, Silakari C, et al. Current and novel therapeutic molecules and targets in Alzheimer's disease. J Formos Med Assoc 2015; 25: 3–10.
17. Ikeda K, Akiyama H, Kondo H, Haga C. A study of dementia with argyrophilic grains. Possible cytoskeletal abnormality in dendrospinal portion of neurons and oligodendroglia. Acta Neuropathol 1995; 89: 409–414.
18. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263–269.
19. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47: 1–9.
20. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.
21. Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 2007; 130(Pt 6): 1552–1565.
22. 18F]THK-5117 positron emission tomography. PLoS One 2015; 10: e0140311.